US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

GRAIL Inc

us-stock
To Invest in {{usstockname}}
us-stock
$101.4 0.0391(3.91%) GRAL at 04 Dec 2025 04:33 PM Diagnostics & Research
Lowest Today 93.43
Highest Today 101.294
Today’s Open 96.53
Prev. Close 97.38
52 Week High 115.76
52 Week Low 16.10
Day’s Range: Low 93.43 High 101.294
52-Week Range: Low 16.10 High 115.76
1 day return -
1 Week return -7.74
1 month return +25.39
3 month return +202.21
6 month return +152.63
1 year return +398.91
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 1

Buy: 0

Hold: 3

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3796.09 M

PB Ratio 1.9211

PE Ratio 0.0

Enterprise Value 3821.71 M

Total Assets 2983.31 M

Volume 1232217

Company Financials

Annual Revenue FY23:93105000 93.1M

Annual Profit FY23:-95611000 -95.6M

Annual Net worth FY23:-1283652000 -1283.7M

Quarterly Revenue Q3/2025:36194000 36.2M, Q2/2025:35544000 35.5M, Q1/2025:31837000 31.8M, Q3/2024:28652000 28.7M, Q2/2024:31970000 32.0M

Quarterly Profit Q3/2025:-13733000 -13.7M, Q2/2025:-17775000 -17.8M, Q1/2025:-19929000 -19.9M, Q3/2024:-22233000 -22.2M, Q2/2024:-17912000 -17.9M

Quarterly Net worth Q3/2025:-88977000 -89.0M, Q2/2025:-113985000 -114.0M, Q1/2025:-106213000 -106.2M, Q3/2024:-125688000 -125.7M, Q2/2024:-1585337000 -1585.3M

Fund house & investment objective

Company Information GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Organisation Diagnostics & Research

Employees 1000

Industry Diagnostics & Research

CEO Mr. Robert P. Ragusa

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right